Document Classification

Section Type: RESULTS

Text: However, key secondary endpoints were met : the mean 4 h C-peptide AUC was significantly higher (mean increase of 0. 015 nmol/L [95 % CI -0. 076 to 0. 106] vs decrease of -0. 156 nmol/L [-0. 305 to -0. 006] ; p = 0. 019), and daily insulin use (0. 48 units per kg per day for placebo vs 0. 36 units per kg per day for alefacept ; p = 0. 02) and the rate of hypoglycaemic events (mean of 10. 9 events per person per year for alefacept vs 17. 3 events for placebo ; p < 0. 0001) was significantly lower at 12 months in the alefacept group than in the placebo group.